Monday, December 9, 2024

CATEGORY

Moderna

Positive EMA Opinion for Moderna’s JN.1 Variant Vaccine

Key Takeaways:Moderna's updated COVID-19 mRNA vaccine, targeting the JN.1 variant EMA’s positive opinion marks a significant milestone in ensuring public health protection Moderna’s...

COVID-19 Vaccine Targeting JN.1 Variant Approved by Taiwan FDA for Broad Immunization

Key TakeawaysThe Taiwan FDA has approved Moderna’s updated Spikevax COVID-19 vaccine, targeting the JN.1 variant, for individuals six months and older, expanding protection...

COVID-19 Vaccine Targeting JN.1 Variant Receives MHRA Approval, Expanding Access Through NHS and Private Purchase

Key TakeawaysModerna’s updated Spikevax® JN.1 COVID-19 vaccine has received MHRA approval in the UK, targeting the JN.1 Omicron subvariant to protect high-risk individuals...

Japan Approves Moderna’s Updated COVID-19 Vaccine Targeting JN.1 Variant

Key Takeaways:Japan’s Ministry of Health has approved Moderna’s updated COVID-19 vaccine, targeting the JN.1 variant. The vaccine aligns with WHO recommendations and is...

Moderna’s mRESVIA Vaccine Approved by European Commission for RSV

Key Takeaways:Moderna’s mRESVIA vaccine has received European Commission approval for protecting adults aged 60+ against RSV. The approval is based on robust clinical...

Moderna and Mitsubishi Tanabe Partner to Promote mRNA Vaccines in Japan

Moderna, Inc. and Mitsubishi Tanabe Pharma Corporation announced a joint agreement for the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including its...

Respiratory Syncytial Virus Vaccine mRESVIA by Moderna Receives Positive CHMP Opinion, Awaiting EU Approval

Moderna's novel mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA, has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products...

Geographic Atrophy Treatments Face Setbacks as EU Drug Regulator Rejects Apellis’ Syfovre Again

For the second time in six months, the European Medicines Agency's (EMA) European Committee for Medicinal Products for Human Use (CHMP) has rejected Apellis’...

Respiratory Syncytial Virus Vaccine mResvia Gains FDA Approval, Bolstering Moderna’s Market Position

Respiratory syncytial virus (RSV) vaccine mResvia (formerly mRNA-1345) has secured FDA approval, marking a significant milestone for Moderna as it seeks to diversify its...

FDA Delays Moderna’s Respiratory Syncytial Virus Vaccine Approval; Company Aims for Quick Resolution

Moderna, renowned for its groundbreaking contributions to combatting the COVID-19 pandemic with its innovative vaccines, embarked on a new frontier by venturing into the...

Artificial Intelligence Elevates Moderna’s Pioneering mRNA Medicine Development

Moderna has been a pioneer at the intersection of science, technology, and health, embracing machine learning and artificial intelligence (AI) since its inception to...

Eli Lilly, Novo Nordisk, Moderna and Regeneron Post Strong Quarterly Earnings Owing to Successful Development Initiatives

Eli Lilly, Novo Nordisk, Moderna, and Regeneron achieved robust quarterly earnings, attributing it to the success of their drug and pipeline development initiatives. Eli...

Moderna and Caris Life Sciences Join Forces for Advancement in mRNA-Based Oncology Therapeutics Using Health Data

An agreement has been reached where Moderna will use Caris Life Sciences' library of de-identified, multi-modal health data solutions. These solutions have been generated...

Latest news